Insitro CEO Daphne Koller discusses using AI to accelerate clinical trials

STAT+ AI Prognosis newsletter featured an interview with Insitro chief executive Daphne Koller about the role of artificial intelligence in drug discovery and how it could speed up clinical trials.

Koller explained that AI models can sift through large datasets to pinpoint promising drug candidates earlier, allowing trial designs to focus on the most likely successes and potentially shortening development timelines.

She also highlighted challenges, including the need for high‑quality data, regulatory acceptance of AI‑driven decisions, and the importance of collaboration between biotech firms, academia, and regulators.

The conversation is part of STAT+’s subscriber‑only content, encouraging readers interested in health‑tech to subscribe for deeper analysis and future AI‑focused stories.